news Team identifies T-cell epitopes to inform COVID-19 vaccine development 2 October 2020 | By Victoria Rees (Drug Target Review) Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
news Bioengineered vaccine shows efficacy at protecting mice from COVID-19 3 September 2020 | By Victoria Rees (Drug Target Review) Researchers have developed a novel vaccine using nucleotide untranslated regions that successfully protected mice from COVID-19.
news Genetic analysis of SARS-CoV-2 reveals one vaccine could combat all infections 2 September 2020 | By Victoria Rees (Drug Target Review) A genetic analysis of SARS-CoV-2 sequences reveal the virus has mutated minimally since December 2019, suggesting only one vaccine is needed to combat COVID-19.
news Tracking SARS-CoV-2 evolution: notable mutations and potential targets 26 August 2020 | By Hannah Balfour (Drug Target Review) Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
news COVID-19 vaccine elicits high levels of neutralising antibodies in mice 17 August 2020 | By Victoria Rees (Drug Target Review) A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
news Potential COVID-19 treatment and vaccine combination shows success in cells 12 August 2020 | By Victoria Rees (Drug Target Review) A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
news Atomic-scale details of SARS-CoV-2 Spike protein from vaccine obtained 11 August 2020 | By Victoria Rees (Drug Target Review) The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
article Coronavirus update: COVID-19 vaccine pre-clinical developments 5 August 2020 | By Victoria Rees (Drug Target Review) Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
news Majority of T-cell targets not on COVID-19 Spike protein, study finds 31 July 2020 | By Victoria Rees (Drug Target Review) Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
news Team redesigns COVID-19 Spike protein for more stable vaccines 24 July 2020 | By Victoria Rees (Drug Target Review) Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
news Nanoparticle COVID-19 vaccine elicits immune response in pre-clinical studies 21 July 2020 | By Hannah Balfour (Drug Target Review) The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
news Most antibodies targeting SARS-CoV-2 use specific immunoglobulin subtype 14 July 2020 | By Hannah Balfour (Drug Target Review) Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
article Prophylactics for COVID-19 – known and unknown 9 July 2020 | By Alan Olan This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.
news Macaques develop short-term immunity to SARS-CoV-2 6 July 2020 | By Hannah Balfour (Drug Target Review) Researchers experimenting on macaques reveal they were protected against reinfection up to a month after the initial exposure to SARS-CoV-2.
news MMR vaccine could protect against COVID-19 sepsis, paper says 22 June 2020 | By Victoria Rees (Drug Target Review) Researchers have suggested that the MMR live attenuated vaccine could be used to provide non-specific protection to patients against sepsis associated with COVID-19.
